Literature DB >> 22076974

Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders.

Laura R Schaevitz1, Jonathan D Picker, Jasmine Rana, Nancy H Kolodny, Barry Shane, Joanne E Berger-Sweeney, Joseph T Coyle.   

Abstract

Interactions between genetic and environmental risk factors underlie a number of neuropsychiatric disorders, including schizophrenia (SZ) and autism (AD). Due to the complexity and multitude of the genetic and environmental factors attributed to these disorders, recent research strategies focus on elucidating the common molecular pathways through which these multiple risk factors may function. In this study, we examine the combined effects of a haplo-insufficiency of glutamate carboxypeptidase II (GCPII) and dietary folic acid deficiency. In addition to serving as a neuropeptidase, GCPII catalyzes the absorption of folate. GCPII and folate depletion interact within the one-carbon metabolic pathway and/or of modulate the glutamatergic system. Four groups of mice were tested: wild-type, GCPII hypomorphs, and wild-types and GCPII hypomorphs both fed a folate deficient diet. Due to sex differences in the prevalence of SZ and AD, both male and female mice were assessed on a number of behavioral tasks including locomotor activity, rotorod, social interaction, prepulse inhibition, and spatial memory. Wild-type mice of both sexes fed a folic acid deficient diet showed motor coordination impairments and cognitive deficits, while social interactions were decreased only in males. GCPII mutant mice of both sexes also exhibited reduced social propensities. In contrast, all folate-depleted GCPII hypomorphs performed similarly to untreated wild-type mice, suggesting that reduced GCPII expression and folate deficiency are mutually protective. Analyses of folate and neurometabolite levels associated with glutamatergic function suggest several potential mechanisms through which GCPII and folate may be interacting to create this protective effect.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22076974      PMCID: PMC3401954          DOI: 10.1002/dneu.21000

Source DB:  PubMed          Journal:  Dev Neurobiol        ISSN: 1932-8451            Impact factor:   3.964


  69 in total

1.  Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia.

Authors:  A M Devlin; E H Ling; J M Peerson; S Fernando; R Clarke; A D Smith; C H Halsted
Journal:  Hum Mol Genet       Date:  2000-11-22       Impact factor: 6.150

2.  Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure.

Authors:  Daniel Kondziella; Eiliv Brenner; Elvar M Eyjolfsson; Katarina Ryden Markinhuhta; Maria L Carlsson; Ursula Sonnewald
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

3.  N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells.

Authors:  B Wroblewska; J T Wroblewski; S Pshenichkin; A Surin; S E Sullivan; J H Neale
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

4.  Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice.

Authors:  Yuto Takatsu; Yuko Fujita; Takashi Tsukamoto; Barbara S Slusher; Kenji Hashimoto
Journal:  Brain Res       Date:  2010-11-18       Impact factor: 3.252

5.  Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition.

Authors:  Z Chen; A C Karaplis; S L Ackerman; I P Pogribny; S Melnyk; S Lussier-Cacan; M F Chen; A Pai; S W John; R S Smith; T Bottiglieri; P Bagley; J Selhub; M A Rudnicki; S J James; R Rozen
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

6.  Folate supplementation in schizophrenia: a possible role for MTHFR genotype.

Authors:  Michele Hill; Kelsey Shannahan; Sarah Jasinski; Eric A Macklin; Lisa Raeke; Joshua L Roffman; Donald C Goff
Journal:  Schizophr Res       Date:  2011-02-21       Impact factor: 4.939

7.  Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome.

Authors:  Nupur Nag; Joanne E Berger-Sweeney
Journal:  Neurobiol Dis       Date:  2007-02-13       Impact factor: 5.996

8.  One-carbon metabolism and schizophrenia: current challenges and future directions.

Authors:  M O Krebs; Alfredo Bellon; Gaell Mainguy; T M Jay; Helge Frieling
Journal:  Trends Mol Med       Date:  2009-11-05       Impact factor: 11.951

Review 9.  Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism.

Authors:  B Shane
Journal:  Vitam Horm       Date:  1989       Impact factor: 3.421

10.  Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites.

Authors:  H M Valivullah; J Lancaster; P M Sweetnam; J H Neale
Journal:  J Neurochem       Date:  1994-11       Impact factor: 5.372

View more
  4 in total

Review 1.  Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.

Authors:  Asma Khan; Susan B Powell
Journal:  Schizophr Res       Date:  2017-10-22       Impact factor: 4.939

Review 2.  Ability of dietary factors to affect homocysteine levels in mice: a review.

Authors:  Christine Brütting; Pia Hildebrand; Corinna Brandsch; Gabriele I Stangl
Journal:  Nutr Metab (Lond)       Date:  2021-06-30       Impact factor: 4.169

3.  Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients.

Authors:  Baohua Zhang; Mei Han; Shuping Tan; Fu De Yang; Yunlong Tan; Shurong Jiang; Xiangyang Zhang; Xu-Feng Huang
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

4.  Profound changes in cerebrospinal fluid proteome and metabolic profile are associated with congenital hydrocephalus.

Authors:  Alicia Requena-Jimenez; Mohammad Nabiuni; Jaleel A Miyan
Journal:  J Cereb Blood Flow Metab       Date:  2021-08-20       Impact factor: 6.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.